Bioapplications Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Vaccine composition for classical swine fever from plant and manufacturing method thereof (US 10,344,293) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Recombinant Vector for Expressing Target Protein in Plant Cell (US 11,845,945) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Recombinant canine parvovirus 2a VP2 and 2b VP2 antigen protein, and use thereof (US 11,958,883) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Sep 1 US 12,721,887 Vaccine Composition Comprising Plant-Expressed Recombinant Zika Virus Envelope Protein and Preparation Method Therefor
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,512,173 | Method for separating and purifying protein from plants using cellulose and cellulose binding domain In force · USPTO record | In force | USPTO record | |
| US 10,344,293 | Vaccine composition for classical swine fever from plant and manufacturing method thereof In force · USPTO record | In force | USPTO record | |
| US 11,279,943 | Recombinant Vector for Expressing Target Protein in Plant Cell In force · High confidence | In force | High confidence | |
| US 11,845,945 | Recombinant Vector for Expressing Target Protein in Plant Cell In force · High confidence | In force | High confidence | |
| US 10,934,558 | Recombinant vector carrying cellulose binding domain and method for isolating and purifying protein, using same vector In force · USPTO record | In force | USPTO record | |
| US 10,857,217 | Antigen Fused with Porcine FC Fragment and Vaccine Composition Comprising the Same In force · Medium confidence | In force | Medium confidence | |
| US 10,947,278 | Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof In force · USPTO record | In force | USPTO record | |
| US 11,434,496 | Recombinant vector comprising BiP fragment and preparation method of recombinant proteins using thereof In force · USPTO record | In force | USPTO record | |
| US 11,958,883 | Recombinant canine parvovirus 2a VP2 and 2b VP2 antigen protein, and use thereof In force · USPTO record | In force | USPTO record | |
| US 12,385,056 | Method for Mass Production of Target Protein in Plant In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 1 patent in force now held by others · 5 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 4 abandoned · 4 no status recorded
Showing 1 to 10 of 10, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/686,801 | Vaccine for Preventing African Swine Fever, Comprising African Swine Fever Virus-Derived Antigen Protein | Aug 12, 2022 | Pending |
| 18/580,550 | Plant-Based COVID-19 Variant Recombinant Spike Protein Expression Vector and Recombinant Protein Using Same | Jul 19, 2022 | Abandoned |
| 18/279,038 | Method for Producing Alfalfa Mosaic Virus-Like Particles Using Plant Expression System and Use Thereof | Feb 11, 2022 | Pending |
| 17/995,872 | Apr 22, 2021 | Abandoned | |
| 17/920,526 | Apr 22, 2021 | Abandoned | |
| 17/759,740 | Mar 12, 2021 | No status recorded | |
| 16/964,632 | Jun 29, 2020 | No status recorded | |
| 16/964,629 | Jun 16, 2020 | No status recorded | |
| 17/601,128 | Apr 1, 2020 | No status recorded | |
| 17/426,275 | Vaccine Composition for Preventing Tuberculosis, Comprising Glycosylated AG85A Protein and Method for Preparing Same | Jan 23, 2020 | Abandoned |